Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Does comorbid depression and anxiety portend poor long-term outcomes following surgery for lumbar spondylolisthesis? Five-year analysis of the Quality Outcomes Database
DiDomenico, Joseph D., Virk, Michael S., Godzik, Jakub , Johnson, Sarah E. , Bydon, Mohamad , Mummaneni, Praveen V. , Bisson, Erica F. , Glassman, Steven D. , Chan, Andrew K. , Chou, Dean , Fu, Kai-Ming, Shaffrey, Christopher I., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Knightly, John J. , Shaffrey, Mark E., Slotkin, Jonathan R., Haid, Regis W., Turner, Jay D. , Farber, Samuel Harrison , Virk, Michael S., Shaffrey, Christopher I. , Park, Paul , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | September 7, 2024 | Volume: 41 | Issue: 5 | Pages: 579-588

10.3171/2024.5.spine24325 | PMID 39241264 Get It

OBJECTIVE Depression and anxiety are associated with poor outcomes following spine surgery. However, the influence of these conditions on achieving a minimal clinically important difference (MCID) following lumbar spine surgery, as well as the potential compounding effects of comorbid depression and anxiety, is not well understood. This study explores the impact of comorbid depression and anxiety on long-term clinical outcomes following surgical treatment for degenerative lumbar spondylolisthesis. METHODS This study was a retrospective analysis of the multicenter, prospectively collected Quality Outcomes Database (QOD). Patients with surgically treated grade 1 lumbar spondylolisthesis from 12 centers were included. Preoperative baseline characteristics and comorbidities were recorded, including self-reported depression and/or anxiety. Pre- and postoperative patient-reported outcomes (PROs) were recorded: the numeric rating scale (NRS) score for back pain (NRS-BP), NRS score for leg pain (NRS-LP), Oswestry Disability Index (ODI), and EQ-5D. Patients were grouped into 3 cohorts: no self-reported depression or anxiety (non-SRD/A), self-reported depression or anxiety (SRD/A), or presence of both comorbidities (SRD+A). Changes in PROs over time, satisfaction rates, and rates of MCID were compared. A multivariable regression analysis was performed to establish independent associations. RESULTS Of the 608 patients, there were 452 (74.3%) with non-SRD/A, 81 (13.3%) with SRD/A, and 75 (12.3%) with SRD+A. Overall, 91.8% and 80.4% of patients had ≥ 24 and ≥ 60 months of follow-up, respectively. Baseline PROs were universally inferior for the SRD+A cohort. However, at 60-month follow-up, changes in all PROs were greatest for the SRD+A cohort, resulting in nonsignificant differences in absolute NRS-BP, NRS-LP, ODI, and EQ-5D across the 3 groups. MCID was achieved for the SRD+A cohort at similar rates to the non-SRD/A cohort. All groups achieved > 80% satisfaction rates with surgery without significant differences across the cohorts (p = 0.79). On multivariable regression, comorbid depression and anxiety were associated with worse baseline PROs, but they had no impact on 60-month PROs or 60-month achievement of MCIDs. CONCLUSIONS Despite lower baseline PROs, patients with comorbid depression and anxiety achieved comparable rates of MCID and satisfaction after surgery for lumbar spondylolisthesis to those without either condition. This quality-of-life benefit was durable at 5-year follow-up. These data suggest that patients with self-reported comorbid depression and anxiety should not be excluded from consideration of surgical intervention and often substantially benefit from surgery.
Multiparametric MRI Scoring System of the Pancreas for the Diagnosis of Chronic Pancreatitis
Tirkes, Temel , Yadav, Dhiraj , Conwell, Darwin L. , Zhao, Xuandong, Dasyam, Anil K. , Halappa, Vivek Gowdra, Patel, Aashish, Shah, Zarine K. , Swensson, Jordan , Takahashi, Naoki , Wachsman, Ashley, Yang, Yunlong, Hart, Phil A. , Park, Walter G. , Vege, Santhi Swaroop , Topazian, Mark , Territo, Paul R. , Persohn, Scott A., Andersen, Dana K. , Fogel, Evan L. , Venkatesh, Sudhakar K , Takahashi, Naoki , Dasyam, Anil K , Venkatesh, Sudhakar K. , Li, Liang , Jennings, Kristofer , Pandol, Stephen J.

Mayo Clinic

Journal of Magnetic Resonance Imaging | September 3, 2024 | Volume: 61 | Issue: 5 | Pages: 2183-2194

10.1002/jmri.29594 | PMID 39225586 Get It

BackgroundDuctal features alone may not offer high diagnostic sensitivity or most accurate disease severity of chronic pancreatitis (CP).PurposeDiagnose CP based on multiparametric MRI and MRCP features.Study TypeProspective.PopulationBetween February 2019 and May 2021, 46 control (23 males, 49.3 ± 14.1 years), 45 suspected (20 males, 48.7 ± 12.5 years), and 46 definite (20 males, 53.7 ± 14.6 years) CP patients were enrolled at seven hospitals enrolled in the MINIMAP study. CP classification was based on imaging findings and clinical presentation.Field Strength and Sequences1.5 T. T1‐weighted (T1W) spoiled gradient echo, T1 map with variable flip angle, dual‐echo Dixon, secretin‐enhanced MRCP before and after secretin infusion.AssessmentDual‐echo fat fraction (FF), T1 relaxation time, extracellular volume (ECV), T1 signal intensity ratio of the pancreas to the spleen (T1 score), arterial‐to‐venous enhancement ratio (AVR), pancreatic tail diameter (PTD), pancreas volume, late gadolinium enhancement, pancreatic ductal elasticity (PDE), and duodenal filling grade of secretin‐enhanced MRCP were measured.Statistical TestsLogistic regression analysis generated CP‐MRI and secretin‐enhanced CP‐SMRI scores. Receiver operating characteristics analysis was used to differentiate definite CP from control. Interobserver agreement was assessed using Lin's concordance correlation coefficient.ResultsCompared to control, definite CP cohort showed significantly higher dual‐echo FF (7% vs. 11%), lower AVR (1.35 vs. 0.85), smaller PTD (2.5 cm vs. 1.95 cm), higher ECV (28% vs. 38%), and higher incidence of PDE loss (6.5% vs. 50%). With the cut‐off of >2.5 CP‐MRI score (dual‐echo FF, AVR, and PTD) and CP‐SMRI score (dual‐echo FF, AVR, PTD, and PDE) had cross‐validated area under the curves of 0.84 (sensitivity 87%, specificity 68%) and 0.86 (sensitivity 89%, specificity 67%), respectively. Interobserver agreement for both CP‐MRI and CP‐SMRI scores was 0.74.ConclusionThe CP‐MRI and CP‐SMRI scores yielded acceptable performance and interobserver agreement for the diagnosis of CP.Evidence Level1Technical EfficacyStage 2
Immobile Left Arm in a 2-month-old Infant
Hadley, J, Koti, Ajay , Johnson, Katie L. , Brown, Emily , Hadley, Julia C.

Mayo Clinic

Pediatrics in Review | September 1, 2024 | Volume: 45 | Issue: 9 | Pages: e33-e36

10.1542/pir.2023-006170 | PMID 39217125 Get It

Predictors of patient satisfaction after surgery for grade 1 degenerative spondylolisthesis: a 5-year analysis of the Quality Outcomes Database
Dru, Alexander, Johnson, Sarah E. , Linzey, Joseph R. , Foley, Kevin T. , DiGiorgio, Anthony M. , Alan, Nima , Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Knightly, John J. , Fu, Kai-Ming, Shaffrey, Mark E., Weaver, Jason, Bydon, Mohamad , Chou, Dean , Meyer, Scott A., Asher, Anthony L. , Shaffrey, Christopher I. , Slotkin, Jonathan R., Wang, Michael Y. , Haid, Regis W., Glassman, Steven D. , Virk, Michael S. , Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | August 31, 2024 | Volume: 41 | Issue: 5 | Pages: 658-665

10.3171/2024.5.spine24227 | PMID 39213671 Get It

OBJECTIVE Lumbar decompression and/or fusion surgery is a common operation for symptomatic lumbar spondylolisthesis refractory to conservative management. Multiyear follow-up of patient outcomes can be difficult to obtain but allows for identification of preoperative patient characteristics associated with durable pain relief, improved functional outcome, and higher patient satisfaction. METHODS A query of the Quality Outcomes Database (QOD) low-grade spondylolisthesis module for patients who underwent surgery for grade 1 lumbar spondylolisthesis (from July 2014 to June 2016 at the 12 highest-enrolling sites) was used to identify patient satisfaction, as measured with the North American Spine Society (NASS) questionnaire, which uses a scale of 1–4. Patients were considered satisfied if they had a score ≤ 2. Multivariable logistic regression was performed to identify baseline demographic and clinical predictors of long-term satisfaction 5 years after surgery. RESULTS Of 573 eligible patients from a cohort of 608, patient satisfaction data were available for 81.2%. Satisfaction (NASS score of 1 or 2) was reported by 389 patients (83.7%) at 5-year follow-up. Satisfied patients were predominantly White and ambulation independent and had lower baseline BMI, lower back pain levels, lower Oswestry Disability Index (ODI) scores, and greater EQ-5D index scores at baseline when compared to the unsatisfied group. No significant differences in reoperation rates between groups were reported at 5 years. On multivariate analysis, patients who were independently ambulating at baseline had greater odds of long-term satisfaction (OR 1.12, p = 0.04). Patients who had higher 5-year ODI scores (OR 0.99, p < 0.01) and were uninsured (OR 0.43, p = 0.01) were less likely to report long-term satisfaction. CONCLUSIONS Lumbar surgery for the treatment of grade 1 spondylolisthesis can provide lasting pain relief with high patient satisfaction. Baseline independent ambulation is associated with a higher long-term satisfaction rate after surgery. Higher ODI scores at 5-year follow-up and uninsured status are associated with lower postoperative long-term satisfaction.
Association of COVID-19 Vaccination With Risk of Medically Attended Postacute Sequelae of COVID-19 During the Ancestral, Alpha, Delta, and Omicron Variant Eras
Swift, Melanie D. , Breeher, Laura E. , Dierkhising, Ross , Hickman, Joel , Johnson, Matthew G. , Roellinger, Daniel , Virk, Abinash , Roellinger, Daniel L , Swift, Melanie D , Breeher, Laura , Johnson, Matthew G

Mayo Clinic

Open Forum Infectious Diseases | August 28, 2024 | Volume: 11 | Issue: 9 | Pages: No page available

10.1093/ofid/ofae495 | PMID 39290777 Get It

Abstract Background Uncertainty exists regarding the effectiveness of COVID-19 vaccine to prevent postacute sequelae of COVID-19 (PASC) following a breakthrough infection. While most studies based on symptom surveys found an association between preinfection vaccination status and PASC symptoms, studies of medically attended PASC are less common and have reported conflicting findings. Methods In this retrospective cohort of patients with an initial SARS-CoV-2 infection who were continually empaneled for primary care in a large US health system, the electronic health record was queried for preinfection vaccination status, demographics, comorbidity index, and diagnosed conditions. Multivariable logistic regression was used to model the outcome of a medically attended PASC diagnosis within 6 months of SARS-CoV-2 infection. Likelihood ratio tests were used to assess the interaction between vaccination status and prevalent variant at the time of infection and between vaccination status and hospitalization for SARS-CoV-2 infection. Results During the observation period, 6.9% of patients experienced medically attended and diagnosed PASC. A diagnosis of PASC was associated with older age, female sex, hospitalization for the initial infection, and an increased severity-weighted comorbidity index and was inversely associated with infection during the Omicron period. No difference in the development of diagnosed PASC was observed between unvaccinated patients and those vaccinated with either 2 doses of an mRNA vaccine or &gt;2 doses. Conclusions We found no association between vaccination status at the time of infection and development of medically diagnosed PASC. Vaccine remains an important measure to prevent SARS-CoV-2 infection and severity. Further research is needed to identify effective measures to prevent and treat PASC.
Repetitive Head Impacts and Perivascular Space Volume in Former American Football Players
Jung, Leonard , Wiegand, Tim L. T. , Tuz‐Zahra, Fatima , Iliff, Jeffrey J. , Piantino, Juan , Arciniega, Hector , Kim, Cara L., Pankatz, Lara, Lin, Alexander , Alosco, Michael L. , Daneshvar, Daniel H. , Pasternak, Ofer , Coleman, Michael J. , Bernick, Charles , Balcer, Laura J. , Reiman, Eric M. , Shenton, Martha E., Protas, Hillary , Boker, Conni, Kowall, Neil W. , Otis, James , Weller, Jason , Simkin, Irene, Andino, Alondra, Diamond, Courtney , Fagle, Tessa, Haller, Olivia, Hung, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen , Nanna, Mary, Platt, Taylor, Pulukuri, Sury, Rica, Fiona, Sestak, Madison, Annis, Douglas S. , Dixon, Dianne B., Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Martin, Brett, Palmisano, Joseph , Pine, Brittany, Fitzsimmons, Jennifer, Breedlove, Katherine M. , Coello, Eduardo , Liao, Hujiun, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah J. , Ritter, Aaron, Sabbagh, Marwan N. , Cruz, Raelynn de la, Durant, Jan, Golceker, Moragn, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Falk, Bryce W., Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Kirov, Ivian, Marmar, Charles R. , Hasanaj, Lisene, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan , Martin, Sammie, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth A. , Marcus, Daniel S. , Gurney, Jenny , Johnson, Keith A. , Greenwald, Richard M., Shenton, Martha E. , Daneshvar, Daniel H , Shenton, Martha E , Tripodis, Yorghos , Bouix, Sylvain , Mez, Jesse , Sepehrband, Farshid , Rathi, Yogesh , Adler, Charles H. , Cummings, Jeffrey L. , Stern, Robert A. , Koerte, Inga K , Su, Yi , Chen, Kewei , Boker, Connie, Au, Rhoda , Cantu, Robert C. , Farrer, Lindsay A. , Helm, Robert H. , Mercier, Gustavo , Conneely, Shannon E. , Diamond, Courtney, Pulukuri, Surya Vamsi , McClean, Michael D , Annis, Douglas, Chaisson, Christine E. , Finney, Carolyn, Lü, Jun , Ojo, Emmanuel, Ramachandran, Janani , Bonke, Elena M. , Breedlove, Katherine , Miller, Jason Rafe , II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Wethe, Jennifer V. , Falk, Bryce, Montague, Michelle, Barr, William , Goldberg, Judith D. , Wısnıewskı, Thomas , Lui, Yvonne W. , George, Allan, Riley, Edward P.

Mayo Clinic

JAMA Network Open | August 26, 2024 | Volume: 7 | Issue: 8 | Pages: e2428687

10.1001/jamanetworkopen.2024.28687 | PMID 39186275 Get It

ImportanceExposure to repetitive head impacts (RHI) is associated with increased risk for neurodegeneration. Accumulation of toxic proteins due to impaired brain clearance is suspected to play a role.ObjectiveTo investigate whether perivascular space (PVS) volume is associated with lifetime exposure to RHI in individuals at risk for RHI-associated neurodegeneration.Design, Setting, and ParticipantsThis cross-sectional study was part of the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project, a 7-year multicenter study consisting of 4 US study sites. Data were collected from September 2016 to February 2020 and analyses were performed between May 2021 and October 2023. After controlling for magnetic resonance image (MRI) and processing quality, former American football players and unexposed asymptomatic control participants were included in analyses.ExposurePrior exposure to RHI while participating in American football was estimated using the 3 cumulative head impact indices (CHII-G, linear acceleration; CHII-R, rotational acceleration; and CHII, number of head impacts).Main Outcomes and MeasuresIndividual PVS volume was calculated in the white matter of structural MRI. Cognitive impairment was based on neuropsychological assessment. Linear regression models were used to assess associations of PVS volume with neuropsychological assessments in former American football players. All analyses were adjusted for confounders associated with PVS volume.ResultsAnalyses included 224 participants (median [IQR] age, 57 [51-65] years), with 170 male former football players (114 former professional athletes, 56 former collegiate athletes) and 54 male unexposed control participants. Former football players had larger PVS volume compared with the unexposed group (mean difference, 0.28 [95% CI, 0.00-0.56]; P = .05). Within the football group, PVS volume was associated with higher CHII-R (β = 2.71 × 10−8 [95% CI, 0.50 × 10−8 to 4.93 × 10−8]; P = .03) and CHII-G (β = 2.24 × 10−6 [95% CI, 0.35 × 10−6 to 4.13 × 10−6]; P = .03). Larger PVS volume was also associated with worse performance on cognitive functioning in former American football players (β = −0.74 [95% CI, −1.35 to −0.13]; P = .04).Conclusions and RelevanceThese findings suggest that impaired perivascular brain clearance, as indicated by larger PVS volume, may contribute to the association observed between RHI exposure and neurodegeneration.
Abusive Pediatric Burns Module in the Child Abuse Pediatrics Curriculum for Physicians (CAP-CuP)
Johnson, Katie L. , Crumm, Caitlin E. , Brown, Emily , Johnson, Katie

Mayo Clinic

MedEdPORTAL | August 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11429 | PMID 39184363 Get It

Representation of women in clinical trials supporting FDA ‐approval of contemporary cancer therapies
Kalathoor, Sujay , Ghazi, Sanam , Otieno, Beryl, Babcook, Melissa A., Chen, Sunnia T. , Nidhi, Neha, Bae, Junu, Pierre‐Charles, Jovan , Breathett, Khadijah , Mazimba, Sula , Mohammed, Selma F. , Carter, Rebecca R. , Ferdousi, Mussammat , Kola‐Kehinde, Onaopepo , McLaughlin, Eric , Brammer, Jonathan E. , Ruz, Patrick, Khan, Sarah , Odei, Bismarck , Patel, Prem, Addison, Daniel , Breathett, Khadijah , Nidhi, Neha, Johnson, Amber E , Brewer, LaPrincess C. , Bonsu, Janice M. , Mitchell, Darrion , Wei, Lai , Patel, Prem, Paskett, Electra D.

Mayo Clinic

International Journal of Cancer | August 19, 2024 | Volume: 155 | Issue: 11 | Pages: 1958-1968

10.1002/ijc.35110 | PMID 39155749 Get It

Abstract Contemporary anticancer therapies frequently have different efficacy and side effects in men and women. Yet, whether women are well‐represented in pivotal trials supporting contemporary anticancer drugs is unknown. Leveraging the Drugs@FDA database, clinicaltrials.gov , MEDLINE, and publicly available FDA‐drug‐reviews, we identified all pivotal (phase II and III) non‐sex specific trials supporting FDA‐approval of anticancer drugs (1998–2018). Observed‐enrollment‐rates were compared to expected‐population‐rates derived from concurrent US‐National‐Cancer‐Institute's Surveillance‐Epidemiology‐and‐End‐Results (SEER) reported rates and US‐Census databases. Primary outcome was the proportional representation of women across trials, evaluated by a participation‐to‐prevalence ratio (PPR), according to cancer type. Secondary outcome was the report of any sex‐specific analysis of efficacy and/or safety, irrespective of treatment‐arm. Overall, there were 148 trials, enrolling 60,216 participants (60.5 ± 4.0 years, 40.7% female, 79.1% biologic, targeted, or immune‐based therapies) evaluating 99 drugs. Sex was reported in 146 (98.6%) trials, wherein 40.7% (24,538) were women, compared to 59.3% (35,678) men ( p < .01). Altogether, women were under‐represented in 66.9% trials compared to the proportional incidence of cancers by respective disease type; weight‐average PPR of 0.91 (relative difference: ‐9.1%, p < .01). Women were most under‐represented in gastric (PPR = 0.63), liver (PPR = 0.71), and lung (PPR = .81) cancer trials. Sex‐based safety data was reported in 4.0% trials. There was no association between adequate female enrollment and drug efficacy (HR: 0.616 vs. 0.613, p = .96). Over time, there was no difference in the percentage of women recruited into clinical trials. Among pivotal clinical trials supporting contemporary FDA‐approved cancer drugs, women were frequently under‐represented and sex‐specific‐efficacy and safety‐outcomes were commonly not reported.
Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension
Burger, Charles D. , Tang, Wenze , Tsang, Yuen , Panjabi, Sumeet , Burger, Charles

Mayo Clinic

Pulmonary Circulation | August 18, 2024 | Volume: 14 | Issue: 3 | Pages: No page available

10.1002/pul2.12415 | PMID 39157055 Get It

AbstractSelexipag is an oral selective agonist of the prostacyclin receptor approved to treat adults with pulmonary arterial hypertension (PAH). Selexipag is initiated at a dose of 200 μg twice daily (bid) and usually titrated up by 200 μg bid weekly (per label) or more slowly (e.g., every other week in real‐world clinical practice) to the highest tolerated individualized dose (ID) ranging from 200 to 1600 µg bid. In the Phase 3 GRIPHON trial, selexipag delayed disease progression and reduced risk of PAH‐related hospitalization compared with placebo; the effect was consistent across three prespecified ID groups: low (200–400 µg bid), medium (600–1000 µg bid), and high (1200–1600 µg bid). This study evaluated patient outcomes across selexipag dose ranges in real‐world practice. Data were analyzed from 1186 US adult patients with PAH on selexipag from the Komodo closed‐claims database (2015‒2022). Of these, 634 (53.5%) patients completed titration and reached their selexipag ID (43.8% high ID, 29.8% medium ID, 26.3% low ID). Subsequently, 72.4% of patients in the low ID group had dose adjustments compared with 61.9% (medium ID) and 34.5% (high ID; standardized mean difference 0.63). There were no significant differences in patient outcomes, i,e, persistence (time to discontinuation) and risk of all‐cause and PAH‐related hospitalization across ID groups. The findings in this diverse, real‐world population of patients with PAH reinforced an individualized approach to the dosing scheme to maximize benefit‐risk and achieve the highest tolerated dose with selexipag similar to findings from the GRIPHON trial and other studies.
Cost-effectiveness of posterior lumbar interbody fusion and/or transforaminal lumbar interbody fusion for grade 1 lumbar spondylolisthesis: a 5-year Quality Outcomes Database study
Yee, Timothy J., Liles, Campbell, Johnson, Sarah E. , DiGiorgio, Anthony M. , Alan, Nima , Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Knightly, John J. , Fu, Kai-Ming, Foley, Kevin T. , Shaffrey, Mark E., Bydon, Mohamad , Chou, Dean , Chan, Andrew K. , Meyer, Scott A., Shaffrey, Christopher I. , Slotkin, Jonathan R., Wang, Michael Y. , Haid, Regis W., Glassman, Steven D. , Virk, Michael S., Mummaneni, Praveen V., Ambati, Vardhaan , Asher, Anthony L., Virk, Michael S., Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | August 17, 2024 | Volume: 41 | Issue: 5 | Pages: 596-603

10.3171/2024.5.spine24112 | PMID 39151203 Get It

OBJECTIVE Posterior lumbar interbody fusion (PLIF) and/or transforaminal lumbar interbody fusion (TLIF), referred to as "PLIF/TLIF," is a commonly performed operation for lumbar spondylolisthesis. Its long-term cost-effectiveness has not been well described. The aim of this study was to determine the 5-year cost-effectiveness of PLIF/TLIF for grade 1 degenerative lumbar spondylolisthesis using prospective data collected from the multicenter Quality Outcomes Database (QOD). METHODS Patients enrolled in the prospective, multicenter QOD grade 1 lumbar spondylolisthesis module were included if they underwent single-stage PLIF/TLIF. EQ-5D scores at baseline, 3 months, 12 months, 24 months, 36 months, and 60 months were used to calculate gains in quality-adjusted life years (QALYs) associated with surgery relative to preoperative baseline. Healthcare-related costs associated with the index surgery and related reoperations were calculated using Medicare reimbursement–based cost estimates and validated using price transparency diagnosis-related group (DRG) charges and Medicare charge-to-cost ratios (CCRs). Cost per QALY gained over 60 months postoperatively was assessed. RESULTS Across 12 surgical centers, 385 patients were identified. The mean patient age was 60.2 (95% CI 59.1–61.3) years, and 38% of patients were male. The reoperation rate was 5.7%. DRG 460 cost estimates were stable between our Medicare reimbursement–based models and the CCR-based model, validating the focus on Medicare reimbursement. Across the entire cohort, the mean QALY gain at 60 months postoperatively was 1.07 (95% CI 0.97–1.18), and the mean cost of PLIF/TLIF was $31,634. PLIF/TLIF was associated with a mean 60-month cost per QALY gained of $29,511. Among patients who did not undergo reoperation (n = 363), the mean 60-month QALY gain was 1.10 (95% CI 0.99–1.20), and cost per QALY gained was $27,591. Among those who underwent reoperation (n = 22), the mean 60-month QALY gain was 0.68 (95% CI 0.21–1.15), and the cost per QALY gained was $80,580. CONCLUSIONS PLIF/TLIF for degenerative grade 1 lumbar spondylolisthesis was associated with a mean 60-month cost per QALY gained of $29,511 with Medicare fees. This is far below the well-established societal willingness-to-pay threshold of $100,000, suggesting long-term cost-effectiveness. PLIF/TLIF remains cost-effective for patients who undergo reoperation.